Immunome’s (IMNM) Outperform Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Immunome (NASDAQ:IMNM) in a research report report published on Friday morning, Benzinga reports. Wedbush currently has a $33.00 price objective on the stock.

Separately, Piper Sandler lowered their price target on Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $29.00.

Immunome Trading Up 2.6 %

Shares of NASDAQ IMNM opened at $12.43 on Friday. Immunome has a 12-month low of $6.93 and a 12-month high of $30.96. The company has a market cap of $746.42 million, a P/E ratio of -1.62 and a beta of 1.76. The stock has a fifty day moving average price of $13.89 and a 200 day moving average price of $14.16.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The company had revenue of $2.36 million during the quarter, compared to analyst estimates of $2.62 million. On average, sell-side analysts forecast that Immunome will post -1.92 EPS for the current fiscal year.

Insider Activity

In related news, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the sale, the chief financial officer now owns 47,476 shares of the company’s stock, valued at $760,090.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Immunome news, CFO Max Rosett sold 14,380 shares of Immunome stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total transaction of $230,223.80. Following the transaction, the chief financial officer now directly owns 47,476 shares in the company, valued at approximately $760,090.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jean Jacques Bienaime bought 7,000 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were bought at an average cost of $13.94 per share, with a total value of $97,580.00. Following the purchase, the director now directly owns 16,615 shares in the company, valued at approximately $231,613.10. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. EntryPoint Capital LLC increased its holdings in shares of Immunome by 21,864.0% during the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after purchasing an additional 5,466 shares during the period. Quest Partners LLC acquired a new stake in shares of Immunome during the second quarter worth approximately $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Immunome during the second quarter valued at approximately $97,000. Arizona State Retirement System grew its stake in shares of Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares during the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after purchasing an additional 4,129 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.